WO2023244511A3 - Improved glycan-dependent chimeric antigen receptor cells - Google Patents

Improved glycan-dependent chimeric antigen receptor cells Download PDF

Info

Publication number
WO2023244511A3
WO2023244511A3 PCT/US2023/024956 US2023024956W WO2023244511A3 WO 2023244511 A3 WO2023244511 A3 WO 2023244511A3 US 2023024956 W US2023024956 W US 2023024956W WO 2023244511 A3 WO2023244511 A3 WO 2023244511A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric antigen
glycan
improved
taca
cars
Prior art date
Application number
PCT/US2023/024956
Other languages
French (fr)
Other versions
WO2023244511A2 (en
Inventor
Michael Demetriou
Raymond Wenhou Zhou
Yanni ZHU
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2023244511A2 publication Critical patent/WO2023244511A2/en
Publication of WO2023244511A3 publication Critical patent/WO2023244511A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are chimeric antigen receptors (CARs) specific to tumor-associated carbohydrate antigens (TACA-CARs), vectors encoding the TACA-CARs, and recombinant cells comprising the TACA CARs.
PCT/US2023/024956 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells WO2023244511A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263351746P 2022-06-13 2022-06-13
US63/351,746 2022-06-13

Publications (2)

Publication Number Publication Date
WO2023244511A2 WO2023244511A2 (en) 2023-12-21
WO2023244511A3 true WO2023244511A3 (en) 2024-02-29

Family

ID=89191814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/024956 WO2023244511A2 (en) 2022-06-13 2023-06-09 Improved glycan-dependent chimeric antigen receptor cells

Country Status (1)

Country Link
WO (1) WO2023244511A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190336533A1 (en) * 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
US20210032363A1 (en) * 2017-03-31 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
US20210113709A1 (en) * 2015-05-01 2021-04-22 The Regents Of The University Of California Glycan-dependent Immunotherapeutic Molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210113709A1 (en) * 2015-05-01 2021-04-22 The Regents Of The University Of California Glycan-dependent Immunotherapeutic Molecules
US20190336533A1 (en) * 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
US20210032363A1 (en) * 2017-03-31 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling

Also Published As

Publication number Publication date
WO2023244511A2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
MX2021009087A (en) Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1).
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
AR123362A2 (en) MESOPOROUS SILICA PARTICLE COMPOSITIONS FOR VIRAL DELIVERY
AU2001258567A1 (en) Humanised antibodies to the epidermal growth factor receptor
WO2020069184A3 (en) Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
Yu et al. Targeting glycosphingolipids for cancer immunotherapy
CA2060544A1 (en) Recombinant antibodies specific for a growth factor receptor
ECSP066603A (en) CD20 ANTIBODIES WITH EFFECTOR FUNCTION AND LINK AFFINITY TO THE IMPROVED FC RECEIVER
DE60334700D1 (en) ADCC-RELATED ANTIBODIES TO HLA-DR INDUCING THE PRODUCTION OF CYTOKINS
WO2019232477A3 (en) Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
MX2021012336A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof.
WO2020159754A3 (en) Antibodies specific to cd44
EP0759942A4 (en) Interleukin-15 receptors
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
WO2023244511A3 (en) Improved glycan-dependent chimeric antigen receptor cells
MX2021011887A (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof.
Hanai et al. Recombinant antibodies against ganglioside expressed on tumor cells
WO2023244499A3 (en) Improved glycan-dependent immunotherapeutic bi-specific fusion proteins and chimeric antigen receptors
A Baeuerle et al. Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer
WO2023133358A3 (en) Muc16 chimeric antigen receptors
WO2023244510A3 (en) Improved glycan-dependent immunotherapeutic bi-specific proteins with longer half-life
WO2022159653A8 (en) Bispecific chimeric antigen receptors binding to cd19 and cd22
DK165955C (en) MONOCLONAL ANTIBODIES AGAINST ATRIAL, NATURURETIC PEPTIDES OF MAMMALS, HYBRID CELL LINES, PRODUCING THE ANTIBODIES, PROCEDURES FOR THE PRODUCTION OF THE ANTIBODIES, PROCEDURES FOR THE PRODUCTION OF THE PRODUCTS
WO2022216811A3 (en) Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same
Zhao et al. Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23824455

Country of ref document: EP

Kind code of ref document: A2